In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $0.20 in the prior trading day, X4 Pharmaceuticals Inc (NASDAQ: XFOR) closed at $0.19, down -2.30%. In other words, the price has decreased by -$2.30 from its previous closing price. On the day, 0.9 million shares were traded. XFOR stock price reached its highest trading level at $0.205 during the session, while it also had its lowest trading level at $0.1893.
Ratios:
Our goal is to gain a better understanding of XFOR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.33 and its Current Ratio is at 3.41. In the meantime, Its Debt-to-Equity ratio is 3.53 whereas as Long-Term Debt/Eq ratio is at 3.47.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 12, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $3 previously.
On December 22, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on December 22, 2022, with a $3 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 17 ’24 when Baldry Mark bought 21,646 shares for $0.68 per share. The transaction valued at 14,654 led to the insider holds 115,769 shares of the business.
Baldry Mark bought 13,404 shares of XFOR for $4,598 on Nov 15 ’24. The Chief Commercial Officer now owns 129,173 shares after completing the transaction at $0.34 per share. On Jan 24 ’25, another insider, Ragan Paula, who serves as the President and CEO of the company, sold 76,473 shares for $0.45 each. As a result, the insider received 34,719 and left with 1,087,386 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XFOR now has a Market Capitalization of 33134708 and an Enterprise Value of 9160781. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.94 while its Price-to-Book (P/B) ratio in mrq is 1.47. Its current Enterprise Value per Revenue stands at 3.583 whereas that against EBITDA is -0.065.
Stock Price History:
The Beta on a monthly basis for XFOR is 0.73, which has changed by -0.8595588 over the last 52 weeks, in comparison to a change of 0.05430484 over the same period for the S&P500. Over the past 52 weeks, XFOR has reached a high of $1.39, while it has fallen to a 52-week low of $0.19. The 50-Day Moving Average of the stock is -43.38%, while the 200-Day Moving Average is calculated to be -64.74%.
Shares Statistics:
The stock has traded on average 3.34M shares per day over the past 3-months and 1772980 shares per day over the last 10 days, according to various share statistics. A total of 170.95M shares are outstanding, with a floating share count of 115.02M. Insiders hold about 33.77% of the company’s shares, while institutions hold 30.32% stake in the company. Shares short for XFOR as of 1743379200 were 8075118 with a Short Ratio of 2.42, compared to 1740700800 on 9480584. Therefore, it implies a Short% of Shares Outstanding of 8075118 and a Short% of Float of 4.71.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are keenly observing as 4.0 analysts analyze and rate the current performance of X4 Pharmaceuticals Inc (XFOR) in the stock market.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.32 and -$0.55 for the fiscal current year, implying an average EPS of -$0.46. EPS for the following year is -$0.38, with 5.0 analysts recommending between -$0.23 and -$0.56.
Revenue Estimates
For the next quarter, 6 analysts are estimating revenue of $2.93M. There is a high estimate of $5.6M for the next quarter, whereas the lowest estimate is $1.44M.
A total of 6 analysts have provided revenue estimates for XFOR’s current fiscal year. The highest revenue estimate was $34.63M, while the lowest revenue estimate was $9.8M, resulting in an average revenue estimate of $17.3M. In the same quarter a year ago, actual revenue was $2.56MBased on 6 analysts’ estimates, the company’s revenue will be $33.58M in the next fiscal year. The high estimate is $58.5M and the low estimate is $16.44M.
